Factane (antihemophilic factor) is used as replacement therapy for Factor VIII deficiency, assisting in the temporary control of bleeding episodes in individuals with hemophilia A, a genetic bleeding disorder. This medicine is an option for individuals with hemophilia A, and it may support the reduction of blood loss and assist in addressing bleeding episodes. This offers a key benefit to the patient by assisting with the body's clotting response.

Common clinical scenarios where Factane is used include addressing spontaneous bleeding (such as joint and muscle bleeds), intervening in trauma-related bleeds, and supporting hemostasis during perioperative procedures. Indications addressed by Factane include bleeding in the joint, muscle bleeding, and surgical hemostasis.

“Factane may help provide Factor VIII activity in these patients.”

Quick Fact: Relief for Hemorrhagic Episodes

Who Can and Cannot Use Factane? (Population Eligibility)

Eligibility for Factane (Human Coagulation Factor VIII) is strictly defined by official regulatory documentation and based on a patient's underlying medical condition and physiological status. The medicine is primarily allowed for adult and pediatric patients with Factor VIII deficiency (Hemophilia A), as its use is established across all age groups from infants to older adults.

Eligibility Status	Officially Documented Rule
Contraindicated	Factane must not be used in individuals with a known history of life-threatening immediate hypersensitivity reactions (including anaphylaxis) to Factor VIII or any component of the formulation.
Conditional Use	Use is restricted in two primary groups: 1) Patients who develop Factor VIII neutralizing antibodies (inhibitors), which may restrict continued eligibility for standard use, and 2) Women who are pregnant or lactating, where use is only permitted if deemed clearly needed after medical assessment.

Official regulatory documents do not list specific contraindications based on severe renal or hepatic impairment. Factane is not indicated for the treatment of von Willebrand disease.

Interaction Map: Interactions with other medicines and products — official regulatory information for Factane

Interaction scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	Antifibrinolytic agents (e.g., Tranexamic acid, Aminocaproic acid)
Mechanistic basis of interactions	Pharmacodynamic interaction (additive hemostatic effect)
Timing-based interaction rules	Must not be co-administered in the same IV line or container with any other medicinal product.
Population-specific interaction notes	Not documented in official regulatory labeling.
Interaction-related restrictions	Prohibition against mixing Factane with other solutions or drugs in the same infusion system due to physical-chemical incompatibility.

---

Interaction classifications (high-level)

Classification	Official Regulatory Interpretation
Interaction severity classification	Clinically significant pharmacodynamic interaction (due to documented risk of combined hemostasis effects).
Regulatory basis	Consistent with EMA and FDA Prescribing Information for Factor VIII concentrates.

---

Resulting interaction structure

Official interaction statements:

• The co-administration of Factane with antifibrinolytic agents is officially documented as increasing the risk of thromboembolic events.
• Factane must not be mixed or administered in the same infusion tubing or container with any other medicinal products.
• No conventional metabolic (CYP), transporter-mediated, or exposure-altering drug-drug interactions are documented in regulatory sources.

Connection to the overall interaction profile:

The regulatory documentation defines Factane’s interaction profile primarily through a crucial pharmacodynamic interaction related to its function in coagulation. This structure is supplemented by a mandatory procedural restriction against mixing Factane with other intravenous solutions. Factane is not associated with the common pharmacokinetic interactions (such as CYP enzyme effects) typically seen with small-molecule medicines.

Factane is a replacement strategy that supplies the Human Coagulation Factor VIII ( FVIII) protein, an essential component of the coagulation cascade.

Modulating the Tenase Cofactor Function

Factane supplies the deficient Factor VIII protein, which functions as an essential, non-enzymatic cofactor to Activated Factor IX ( FIXa). This cofactor function facilitates the formation of the Tenase Complex . The resulting physiological effect is the capacity to accelerate the rate of downstream enzymatic reactions in the coagulation cascade.

Generating the Thrombin Burst

The accelerated activation of Factor X ( FX) by the Tenase Complex drives the final steps of the cascade, leading to a rapid, localized release of Thrombin. This provides the necessary concentration of Thrombin to convert Fibrinogen into stable Fibrin polymers. This core mechanism directly results in the polymerization of Fibrin, which constitutes the structural basis of secondary hemostasis.

Mechanism Constraint: Inhibitor Neutralization

The Factor VIII mechanism is constrained by the potential for the immune system to form neutralizing alloantibodies, known as inhibitors. These inhibitors physically bind to the administered FVIII protein, instantly blocking its cofactor function. This physiological immune response overrides the intended mechanism, resulting in the nullification of Factor VIII's cofactor function.

How Factane is Used: Official Administration and Dosing

Factane (Human Coagulation Factor VIII) is exclusively administered via intravenous injection or infusion, as stipulated in official prescribing information. The medication is supplied as a lyophilized powder that requires reconstitution using the provided sterile diluent immediately prior to use. During preparation, the vial must be gently swirled—not shaken—to ensure the protein is not damaged.

---

Dosing Principles

Factane dosing is highly individualized and is determined by the patient’s body weight and the required increase in Factor VIII activity. Doses are always expressed in International Units (IU).

• Dose Calculation: The required IU dose is calculated to achieve a specific target percentage of Factor VIII activity in the blood, often using a formula that incorporates the patient’s weight in kilograms and a recovery factor of approximately 0.5.

• Acute Bleeding: Treatment for a bleeding episode is on-demand and continues only until the bleed is resolved. This typically involves doses given every 8 to 24 hours, depending on the severity and desired clotting factor target.

• Prophylaxis: For preventative use, Factane is administered on a long-term schedule, commonly two or three times per week, to maintain a constant, low trough level of Factor VIII and reduce the frequency of bleeds.

---

Administration Requirements

Feature	Official Use Instruction
Route of Administration	Intravenous Injection or Infusion
Preparation	Must be reconstituted; gently swirl, do not shake.
Infusion Rate	Must be slow; generally not to exceed 10 mL per minute.
Pediatric Use	May require higher or more frequent doses due to faster clearance.

The final solution must be administered using aseptic technique and infusion must proceed slowly. The entire calculated dose must be used immediately after preparation.

Research Evidence / Overview of Studies

Summary of Key Research Findings

Research explored the agent's role in the study of chronic autoimmune conditions in the populations investigated. The research investigated a mechanism involving the inhibition of a key enzyme. This was primarily studied in patients who had not responded adequately to conventional first-line treatments.

Phase 3 Clinical Trials

• Efficacy Studies: Trials primarily focused on assessing specific biological markers and symptom severity scores. Large-scale global studies evaluated the potential to affect the quality of life over a 12-week period. Initial results reported observations of changes in symptoms, and the studies included metrics related to acute increases in disease activity. The trials often included a placebo-controlled arm to observe any differences.
• Long-Term Follow-up: Open-label extension studies continued to observe participants for up to two years. These studies primarily focused on the long-term observation of tolerability and the persistence of previously reported observations. Researchers noted a focus on recording any serious adverse events.

Combination Therapy

Research has also explored the use of this therapy in combination with standard disease-modifying anti-rheumatic drugs (DMARDs). Researchers evaluated whether the combination was associated with better outcomes compared to using the DMARD alone. Findings were mixed, with some subgroup analyses suggesting no notable difference, while other studies reported a trend towards lower disease activity scores in the combined group.

Tolerability Data

The tolerability and safety of the agent were key components of the research. Adverse events reported across major trials included gastrointestinal issues and headaches. Researchers investigated infections of the upper respiratory tract.

• Liver Enzyme Elevations: Elevated liver enzymes were reported in a small percentage of participants. The studies highlighted that elevated liver enzyme levels were often detected, and monitoring of liver function was a component of the research protocols, particularly during the initial months of observation.
• Comparison Studies: Head-to-head trials compared this therapy with existing treatments in a similar class. These studies focused on comparing the incidence rates of adverse events between the treatments, rather than establishing a preference.

Key Studies & References

1. Factane: CT-3967 - Regulatory Evaluation of Human Coagulation Factor VIII in Immune Tolerance Induction (ITI) therapy
2. Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Trial of Synthetic Preimplantation Factor in Autoimmune Hepatitis
3. Efficacy and safety of anticoagulants on venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials

Common questions about Factane (FAQ)

---

Q: Can Factane affect my ability to drive?

Official product information for Factor VIII concentrates, like Factane, documents dizziness as a potential common side effect. Since dizziness can impair a person's concentration, reaction time, and ability to operate equipment, caution is generally advised with activities such as driving or operating machinery. Concerns related to symptoms should be discussed with a healthcare professional.

---

Q: What is the difference between Factane and other treatments for this condition?

Factane is described in regulatory documents as a specific type of Factor VIII concentrate that is plasma-derived, meaning the active Factor VIII protein is sourced from human plasma. Other available treatments may differ by being recombinant (produced using DNA technology) or by being non-factor therapies that work through different mechanisms in the clotting cascade.

---

Q: How does Factane differ from a placebo in research studies?

Clinical studies reviewed by regulatory bodies show that Factane, a Factor VIII replacement therapy, consistently increases the level of Factor VIII activity in the blood. In contrast, a placebo (an inactive substance) would not produce this therapeutic effect. This difference in measurable Factor VIII activity is the intended functional outcome observed in clinical research.

---

Q: What happens if I miss a dose of Factane?

Official regulatory guidance regarding a missed prophylactic dose often recommends infusing the missed dose as soon as the patient remembers. Following the catch-up dose, the regular treatment schedule is typically continued. Official guidance documents caution against administering a double dose to compensate for a missed dose.

---

Q: Is Factane physically addictive or habit-forming?

Regulatory documentation, including sections on drug abuse and dependence, indicates that Factor VIII concentrates are not associated with the potential for physical addiction or dependence. Factane is classified as a prescription-only medicine and is not listed as a controlled substance.

---

Q: Can Factane cause changes in mood or sleep?

While Factor VIII products may list some common systemic reactions such as headache, mood or sleep disturbances (like insomnia or nervousness) are not typically listed among the common or serious side effects in core regulatory profiles. Changes in mood or sleep patterns are generally managed in consultation with a prescribing physician.

---

Q: Are there certain foods or drinks I need to avoid while on Factane?

Official regulatory prescribing information for Factor VIII products generally does not list any specific restrictions on foods or non-alcoholic drinks. There are no documented food-drug interactions listed for Factane. Any significant diet changes are typically reviewed with a healthcare professional.

---

Q: What is the purpose of the black box warning on Factane's label?

Factane, as a Factor VIII concentrate, does not typically carry an FDA Black Box Warning. However, official labeling does include serious warnings that patients should be monitored for the development of Factor VIII inhibitors (neutralizing antibodies) and for immediate hypersensitivity reactions, which can be severe.

---

Q: How long after stopping Factane will it be out of my system?

The length of time Factane stays active in the body is determined by its half-life, which is approximately 12 hours on average for standard Factor VIII concentrates in adults. This means that half of the Factor VIII activity from the dose is eliminated from the plasma in that time, though individual clearance times can vary.

---

Q: What do I do if I think I'm having a rare side effect from Factane?

Regulatory guidance requires patients to report suspected adverse reactions, including rare or unexpected side effects, to the appropriate national health authority (such as the FDA’s MedWatch program or a local Pharmacovigilance Centre). Reporting is necessary to help monitor the product’s overall safety profile after release.

---

Q: Is there a generic version of Factane available?

Factane is a Human Coagulation Factor VIII, which is a complex biological product. Because of this, it is not available as a conventional generic medicine. Other similar versions are available but are known as other brand-name Factor VIII concentrates or, in the case of newer products, biosimilars.

---

Q: Can Factane cause problems with my vision?

Vision problems (such as blurred vision or visual impairment) are not listed as common effects, but regulatory labeling may include them as rare adverse reactions reported from post-marketing experience for Factor VIII products. Vision changes are an effect that would warrant medical assessment.

---

Q: Is Factane appropriate for people with a history of [common chronic condition]?

Regulatory information specifies that Factor VIII products should be used with caution in patients with known cardiovascular risk factors. This caution is due to a potential increased risk of thromboembolic events (blood clots). Potential risk factors related to its use are typically evaluated by a healthcare professional.

---

Q: Are there any known issues with Factane and alcohol consumption?

The official prescribing information for Factane does not contain a specific warning or restriction regarding the consumption of alcohol. As with any long-term therapy, discussion regarding the use of alcohol is typically part of standard patient counseling.

---

Q: What is the difference between the immediate-release and extended-release forms of Factane?

Factane is supplied as a standard Factor VIII concentrate with an average half-life of about 12 hours. Extended half-life Factor VIII products are separate, bioengineered medicines that are specifically designed to prolong the time the product stays active in the bloodstream for a longer period of time than standard concentrates.

---

Q: Is Factane a Schedule [controlled substance number] drug?

Factane (Human Coagulation Factor VIII) is classified as a prescription-only (Rx-only) medicine in major regulatory regions. It is not associated with abuse potential and is not listed as a controlled substance in US, EU, or other national drug schedules.

---

Q: What is the half-life of Factane?

According to the Pharmacokinetics section of the official product labeling, the average half-life for standard Factor VIII concentrates like Factane is approximately 12 hours in adults. This is a measure of how quickly the active dose is cleared from the plasma.

---

Q: What type of healthcare professional usually prescribes Factane?

Regulatory documents recommend that treatment with Factor VIII concentrates should be initiated and supervised by a physician who has specialized experience in the treatment of hemophilia A. This typically means a hematologist or a specialist associated with a hemophilia treatment center.

The storage and disposal of Factane (a lyophilized Factor VIII concentrate) must strictly adhere to regulatory guidelines to ensure stability and safety.

Official Storage Requirements

The unreconstituted powder must be stored in a refrigerator between 2 C and 8 C (36 F and 46 F) until the labeled expiration date. For a limited, product-specific time, Factane may be kept at controlled room temperature (e.g., up to 25 C or 30 C), but once stored at room temperature, it must not be returned to the refrigerator. The vials must be kept in the original carton to protect the contents from light.

• Do not freeze the powder or diluent.
• The reconstituted solution must be administered immediately or within a short, specific timeframe (typically 3 to 8 hours), as stated on the label, and must not be refrigerated after mixing.
• The medicine must be kept out of the sight and reach of children.

Official Disposal Instructions

Discard any unused, expired, or leftover product according to local regulations or a pharmaceutical take-back program. Do not throw the product away in household trash or down the sink/toilet. Used needles, syringes, and other sharps must be placed immediately into a designated, puncture-proof sharps disposal container.